Diffusion Announces Strategic Alliance to Develop New Cancer Therapies

Diffusion Pharmaceuticals LLC, a company that discovers and develops novel small-molecule therapeutics, has reached an agreement with the New Approaches to Brain Tumor Therapy CNS Consortium (NABTT) for a comprehensive clinical trials program to test Diffusion's lead drug candidate, trans sodium crocetinate (TSC), as a radiation sensitizer in the treatment of cancerous tumors. NABTT, an alliance of 10 leading hospitals dedicated to improving the outcome for adults with primary brain tumors, is funded by the National Cancer Institute.

Big News Network

(http://feeds.bignewsnetwork.com/redir.php?jid=6ca28ff7d511a502&cat=6dcd932030878143)